Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Clinical Imbalances

Immune and inflammation

Detoxification and Biotransformation

Gastro-intestinal

Text Availability

Abstract

3715

Full text

3024

Free full text

1701

Publication Types

Journal Article

3759

Research Support, Non-U.S. Gov't

1492

Review

1298

Randomized Controlled Trial

931

Multicenter Study

704

Clinical Trial, Phase II

449

Clinical Trial

357

Clinical Trial, Phase III

345

Comparative Study

309

Clinical Trial, Phase I

230

Research Support, N.I.H., Extramural

229

Systematic Review

171

Meta-Analysis

153

Observational Study

122

Case Reports

117

Research Support, U.S. Gov't, P.H.S.

Controlled Clinical Trial

Letter

Research Support, U.S. Gov't, Non-P.H.S.

Comment

Network Meta-Analysis

Research Support, N.I.H., Intramural

Editorial

Evaluation Study

Clinical Trial, Phase IV

Clinical Trial Protocol

Consensus Development Conference

Practice Guideline

Video-Audio Media

Retracted Publication

Historical Article

Equivalence Trial

Validation Study

Webcast

Guideline

Pragmatic Clinical Trial

Congress

Scoping Review

Interview

Clinical Study

Consensus Statement

Publication Year

From

Quick links

Individual year

2026

2025

193

2024

201

2023

2022

203

2021

253

2020

234

2019

183

2018

153

2017

177

2016

123

2015

228

2014

209

2013

184

2012

192

2011

158

2010

140

2009

136

2008

129

2007

100

2006

106

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Antibodies, Monoclonal""[mesh_terms]

3833 Results

Searching titles within these results

Nemolizumab for atopic dermatitis.

Angelina Labib, Ashley Vander Does, Gil Yosipovitch

Drugs of today (Barcelona, Spain : 1998) 2022;58(4):159-173

Full Text

Abstract

Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years.

M John Chapman, Henry N Ginsberg

Journal of the American College of Cardiology 2020;74(17):2147-2149

Free Full Text

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.

Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J Feinstein, Arman Qamar, Parag H Joshi, Kristopher J Swiger, Kathleen Byrne, Renato Quispe, Steven R Jones, Roger S Blumenthal, Seth S Martin

Future cardiology 2016;12(2):139-48

Full Text

Abstract

Cancer neovascularization and proinflammatory microenvironments.

Mitsuko Furuya, Yoshikazu Yonemitsu

Current cancer drug targets 2008;8(4):253-65

Full Text

Abstract

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.

Future cardiology 2016;12(2):149-57

Full Text

Abstract

Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.

Paul M Ridker, Jean G MacFadyen, Tom Thuren, Peter Libby

European heart journal 2021;41(23):2153-2163

Full Text

Abstract

Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.

Pin-Kuang Lai, Gaurav Ghag, Yao Yu, Veronica Juan, Laurence Fayadat-Dilman, Bernhardt L Trout

mAbs 2022;13(1):1991256

Free Full Text

Abstract

Comparisons of three different doses of alirocumab application in patients with hypercholesterolemia: a meta-analysis.

Yu-Sheng Zhang, Ye-Hua Hao, Hou-Long Luo, Bao-Cheng Xie, Jian-Ying Fu, Zhi-Kun Zhou

Minerva medica 2018;109(3):229-238

Free Full Text

Abstract

Isatuximab in multiple myeloma.

Enrica Antonia Martino, Antonella Bruzzese, Enrico Iaccino, Francesco Mendicino, Selena Mimmi, Eugenio Lucia, Virginia Olivito, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile

Expert opinion on biological therapy 2023;23(4):315-318

Full Text

Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis.

Xiaolei Zhu, Shenhong Wu, Ryan Cheng, Montek Boparai

Cancer investigation 2025;43(5):293-304

Full Text

Abstract

Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltration.

Yinhua Wan, Seshadri Vasan, Raja Ghosh, Geoff Hale, Zhanfeng Cui

Biotechnology and bioengineering 2005;90(4):422-32

Full Text

Abstract

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.

Raja Padidela, Michael P Whyte, Francis H Glorieux, Craig F Munns, Leanne M Ward, Ola Nilsson, Anthony A Portale, Jill H Simmons, Noriyuki Namba, Hae Il Cheong, Pisit Pitukcheewanont, Etienne Sochett, Wolfgang Högler, Koji Muroya, Hiroyuki Tanaka, Gary S Gottesman, Andrew Biggin, Farzana Perwad, Angela Williams, Annabel Nixon, Wei Sun, Angel Chen, Alison Skrinar, Erik A Imel

Calcified tissue international 2021;108(5):622-633

Free Full Text

Abstract

Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.

Thomas F Whayne

American journal of cardiovascular drugs : drugs, devices, and other interventions 2016;16(2):83-92

Full Text

Abstract

Familial hypercholesterolaemia: new treatment options.

M Ezzahti, E J G Sijbrands, M T Mulder, J E Roeters van Lennep

The Netherlands journal of medicine 2014;71(5):227-33

Free Full Text

Abstract

Evolocumab: Considerations for the Management of Hyperlipidemia.

Barbara S Wiggins, Jeffrey Senfield, Helina Kassahun, Armando Lira, Ransi Somaratne

Current atherosclerosis reports 2019;20(4):17

Full Text

Abstract

Results: 1 – 15 / 3833

Filters

Expert Opinion

Clinical Imbalances

Text Availability

Publication Types

Publication Year

Results for ""Antibodies, Monoclonal""[mesh_terms]

Nemolizumab for atopic dermatitis.

Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years.

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.

Cancer neovascularization and proinflammatory microenvironments.

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.

Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.

Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.

Comparisons of three different doses of alirocumab application in patients with hypercholesterolemia: a meta-analysis.

Isatuximab in multiple myeloma.

Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis.

Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltration.

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.

Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.

Familial hypercholesterolaemia: new treatment options.

Evolocumab: Considerations for the Management of Hyperlipidemia.

Results for
""Antibodies, Monoclonal""[mesh_terms]